Table 2.
List of 89Zr-immunoPET tracers that advanced to clinical trials
| ANTIBODY | TARGET | INDICATIONS | CLINICALTRIALS.GOV IDENTIFIER | PHASE AND STATUS |
|---|---|---|---|---|
| Trastuzumab | HER2 | Metastatic HER2+ Breast cancer | NCT01420146 | Phase 1, Completed |
| Metastatic HER2+ Breast cancer; to select patients for T-DM1 treatment | NCT01565200 | Phase 2, Active, not recruiting | ||
| Unsuspected HER2 Breast Metastases | NCT02286843 | Recruiting | ||
| Trastuzumab-resistant Breast Cancer; measure HER2 post-treatment with HSP90 inhibitor AUY922 | NCT01081600 | Phase 1/2, Completed | ||
| Esophagogastric cancer | NCI-2016–00986, NCT02023996 | Phase 1; Recruiting | ||
| HER2+ primary malignancy | NCT03109977 | On-going but not recruiting | ||
| Ibritumomab Tiuxetan | CD20 | Non-hodgkins lymphoma | Complete | |
| Bevacizumab | VEGF | Inflammatory Breast Cancer | NCT01894451 | Phase 1; recruiting |
| Pulmonary arterial hypertension | NCT03166306 | Phase 1/2; not open to recruitment at the time of writing | ||
| huJ591 | PSMA | Prostate cancer | NCT02693860 | Phase 1; recruiting |
| Metastatic prostate cancer | NCT01543659 | Phase 1/2; On-going but not recruiting | ||
| Glioblastoma | NCT02410577 | Phase I, On-going but not recruiting | ||
| Girentuximab | Carbonic Anydrase IX | Renal cell carcinoma | NCT02883153 | Phase 2/3, Completed |
| Cetuximab | EGFR | Stage IV cancer | NCT00691548 | Phase 1; Completed |
| Colorectal cancer | NCT01691391 | Completed | ||
| Ipilimumab | CTLA-4 | Melanoma | NCT03313323 | Phase 2; Recruiting |
| Fresolimumab (GC1008) | TGF-β | Primary brain tumor | NCT01472731 | Phase 2; Completed |
| U36 | CD44v6 | Head and neck cancer | Completed | |
| Pertuzumab | HER2 | HER2 positive malignancy | NCT03109977 | Phase 1; On-going but not recruiting |
| IAb2M | PSMA | Metastatic prostate cancer | NCT01923727 | Phase 1/2, Completed |
| Prostate cancer, pre-prostatectomy | NCT02349022 | Phase 2, Completed | ||
| IAb22M2C | CD8 | Non Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma Head and Neck, Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer, Hodgkin’s Lymphoma | NCT03107663 | Phase 1, Recruiting |
| Rituximab | CD20 | Lung disease, interstitial pneumonitis | NCT02251964 | Phase 2/3; On-going but not recruiting |
| GSK3128349 (Albumin domain binding antibody) | Albumin | Drug related side effects and adverse reactions | NCT02829307 | Phase 1; completed |
| MPDL3280 | PD-L1 | Breast cancer, bladder cancer and non small cell lung cancer | NCT02453984 | Phase 1; recruiting |
| Pembrolizumab | PD-1 | Non small cell lung cancer | NCT03065764 | Phase 2; on-going but not recruiting |
| GSK2849330 | HER3 | Solid tumors | NCT02345174 | Phase 1; Completed |
| AMG211 | HER3 | Advanced gastrointestinal cancer | NCT02760199 | Phase 1; Completed |
| RO5479599 | HER3 | Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors of Epithelial Cell Origin | NCT01482377 | Phase 1; Completed |
| MMOT0530A | Mesothelin | Unresectable pancreatic cancer, platinum-resistant ovarian cancer | NCT01832116 | Phase 1; Completed |
| MSTP2109A | STEAP1 | Prostate cancer | NCT01774071 | Phase 1/2; On-going but not recruiting |
| HuMab-5B1 (MVT-2163) | CA19.9 | Pancreatic Cancer; tumors that express CA19.9 | NCT02687230 | Phase 1; Recruiting |